Brimonidine Tartrate Ophthalmic Solution 0.2% is a relatively selective alpha-2 adrenergic agonist for ophthalmic use. In solution, brimonidine tartrate ophthalmic solution 0.2% has a clear, greenish-yellow color. It has an osmolality of 280-330 mOsml/kg and a pH of 5.6-6.
Brimonidine tartrate ophthalmic solution 0.2% is indicated for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The lOP lowering efficacy of brimonidine tartrate ophthalmic solution 0.2% diminishes over time in some patients. This loss of effect appears with a variable time of onset in each patient and should be closely monitored.
Media Articles Related to Brimonidine ( Ophthalmic)
FDA approves new medication for dry eye disease
Source: Eye Health / Blindness News From Medical News Today [2016.07.12]
The U.S. Food and Drug Administration has approved Xiidra (lifitegrast ophthalmic solution) for the treatment of signs and symptoms of dry eye disease.
Nearly 10 million adults found to be severely nearsighted in the United States
Source: Eye Health / Blindness News From Medical News Today [2016.06.22]
Largest U.S. study of its kind using American Academy of Ophthalmology's national ophthalmic database also finds women at higher risk of potentially blinding complication.
Published Studies Related to Brimonidine ( Ophthalmic)
Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus
bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or
ocular hypertension: a 12-week randomised controlled trial. 
hypertension... CONCLUSIONS: Bimatoprost/timolol PF demonstrated non-inferiority and equivalence
Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of
the OPUS-1 phase 3 study. 
PARTICIPANTS: A total of 588 adult subjects with dry eye disease... CONCLUSIONS: Lifitegrast ophthalmic solution 5.0% significantly reduced corneal
Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple
for multiple sclerosis (MS)... CONCLUSIONS: Fingolimod 0.5 mg is associated with a low incidence of ME in MS
Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic
conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical
Allergic conjunctivitis (AC) affects an estimated 20% of the population in the
Western world, with a large fraction suffering due to seasonal or perennial
allergen exposures. Bepotastine besilate ophthalmic solution (BBOS) 1.5%, a
dual-acting histamine (H(1)) receptor antagonist and mast cell stabilizer, is
indicated for itching associated with AC...
Progesterone increases resistance of ophthalmic and central retinal arteries in
climacteric women. 
compared to placebo, using transorbital ultrasound with Doppler velocimetry... CONCLUSIONS: Our results demonstrate the existence of a progestogenic
Clinical Trials Related to Brimonidine ( Ophthalmic)
Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2% [Completed]
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy [Completed]
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal
administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery
System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.
Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD) [Completed]
Stage 1 is a patient-masked, dose-escalation, safety evaluation of brimonidine intravitreal
implant. Patients will receive implant in one eye and "sham" treatment (meaning no
treatment) in the fellow eye. Stage 2 will begin after 1 month of safety has been evaluated
for Stage 1. Stage 2 is a randomized, double-masked, dose-response, sham-controlled
evaluation of the safety and efficacy of brimonidine intravitreal implant in patients with
geographic atrophy from age-related macular degeneration. Patients will be followed for up
to 2 years.
Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema [Not yet recruiting]
Most patients undergoing cataract surgery suffer from corneal edema after the surgery.
Brimonidine drops are a well known and safe Anti-glaucoma medication. the investigators have
made several clinical observations that patients receiving Brimonidine drops had a faster
resolution of their corneal edema even if they had normal intra-ocular pressure.
The investigators believe that administering topical Brimonidine to patients with
significant post operative corneal edema will hasten the resolution of their corneal edema.
Effect of Brimonidine on Corneal Thickness [Recruiting]
Brimonidine, an alpha-2 adrenoceptor agonist, is an effective and safe medication which is
widely used in glaucoma treatment. Although it is known that it is quickly taken up by the
cornea following topical administration and that the cornea has alpha-2 adrenoceptors there
are only few studies available on the impact brimonidine has on the cornea. The aim of the
study is to find out
1. whether topical administration of brimonidine results in interaction with corneal
alpha-2 adrenoceptors in terms of an increase in corneal thickness and
2. whether there are any differences between the response corneal epithelium, stroma and
endothelium show to alpha-2 adrenoceptor stimulation.